A phase III trial to investigate the efficacy and safety of MI-100 in patients with Stargardt's disease
Phase of Trial: Phase III
Latest Information Update: 04 May 2015
Price : $35 *
At a glance
- Drugs Ecothiopate iodide (Primary)
- Indications Stargardt disease
- Focus Registrational; Therapeutic Use
- Sponsors Makindus
- 04 May 2015 According to a Makindus media release, Makindus recently met with the Food & Drug Administration (FDA) to review a clinical development program to evaluate MI-100 in a Phase 3 program which is plan to start by the end of this year.
- 04 May 2015 According to a Makindus media release, planned initiation date changed from 1 Jan 2015 to 1 Dec 2015.
- 22 Jul 2014 New trial record